Preclinical studies of the home cancer vaccine CaTeVac have been completed, and it is proposed to start using it in 2027. This was reported in the office of the Deputy Prime Minister of the Russian Federation, Tatyana Golikova. In the future, the product may be used to treat melanoma, kidney cancer, primary tumors of the central nervous system and malignant solid tumors where standard treatment has exhausted the options.

Preclinical studies of the home cancer vaccine CaTeVac have been completed, and it is proposed to start using it in 2027. This was reported in the office of the Deputy Prime Minister of the Russian Federation, Tatyana Golikova. In the future, the product may be used to treat melanoma, kidney cancer, primary tumors of the central nervous system and malignant solid tumors where standard treatment has exhausted the options.